Acrux Limited

ASX:ACR ISIN:AU000000ACR3

 Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin. Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. Acrux has also licensed its technology to Eli Lilly for veterinary healthcare products.  
 
     

查看其它語言版本

新聞

6月22日澳洲股市:打破跌勢

🕔6/22/2009 1:00:22 PM 17897

上週五,澳洲股市在一周之中首次收漲。基本指數S&P/ASX200上漲7.5點,或0.19%,報3,899.6點,綜合指數上漲7點,或0.18%,報3894.4點。

閱讀全文
###

45,399 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 19) (過去30日: 93) (自發布以來: 7524) 

公司詳細

    傳真
  • (03) 8379 0101 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.acrux.com.au

更多新聞紀錄

  • 2024/06/13: Acrux presentation at Hidden Gems in Lifesciences Forum*
  • 2024/04/30: Quarterly Activities and Appendix 4C, reissued*
  • 2024/04/30: Quarterly Activities/Appendix 4C Cash Flow Report*
  • 2024/04/03: Launch of Dapsone 5%, Gel in the United States*
  • 2024/03/05: Appendix 3Y Dobinson*
  • 2024/03/05: Appendix 3Y Brumley*
  • 2024/03/05: Application for quotation of securities - ACR*
  • 2024/02/27: Investor Presentation Half Year Accounts*
  • 2024/02/27: Appendix 4D and Half Year Accounts*
  • 2024/02/23: Investor Webinar Details - Financial Results 1H FY24*
*refer to company website